Dichlorphenamide (Keveyis®) is prescribed to prevent attacks of periodic hypokalaemic and hyperkalaemic paralysis, two muscular channelopathies. A post-hoc analysis of the results of the randomized double-blind placebo-controlled HYP-HOP trial and its open-label extension:
- confirms the efficacy of dichlorphenamide at a dose of 100 mg / day in these two indications, with a lasting reduction in the frequency and severity of episodes of transient paralysis in 47 participants, treated for 61 weeks;
- finds undesirable effects such as paresthesias and cognitive disorders (disorientation, memory problems, etc.) occurring especially during the first month of treatment and often resolving thanks to a reduction in the dosage.
At the same time, a North American team has published good results from the same drug in a 24-year-old patient with another form of muscular channelopathy, Andersen Tawil syndrome.
